Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for lung cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Proton Beam Therapy
Photon vs Proton Radiation for Non-Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Philadelphia, Pennsylvania
This trial is comparing two types of radiation therapy to see which is more effective in treating patients with stage II-IIIB non-small cell lung cancer- proton chemoradiotherapy versus photon chemoradiotherapy.
Anti-microtubule agent
Sigvotatug Vedotin vs Docetaxel for Lung Cancer
Recruiting2 awardsPhase 3
Horsham, Pennsylvania
This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.
Checkpoint Inhibitor
Durvalumab + Oleclumab/Monalizumab for Lung Cancer
Recruiting1 awardPhase 3
Philadelphia, Pennsylvania
This trial is testing two drug combinations to help the immune system fight advanced lung cancer that can't be surgically removed. The patients have already had previous treatment without their disease getting worse. The drugs aim to boost the immune response to better identify and kill cancer cells.
Trials With No Placebo
Checkpoint Inhibitor
Atezolizumab + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New Brunswick, New Jersey
This trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after surgery can help people with early-stage lung cancer live longer without their disease coming back.
Tyrosine Kinase Inhibitor
Selpercatinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Dover, Delaware
This trial will study how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer. Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.